{"Symbol": "ANNX", "AssetType": "Common Stock", "Name": "Annexon\u00a0Inc", "Description": "Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. The company is headquartered in South San Francisco, California.", "CIK": "1528115", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "1400 SIERRA POINT PARKWAY, BRISBANE, CA, UNITED STATES, 94005", "OfficialSite": "https://www.annexonbio.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "728883000", "EBITDA": "-216468000", "PERatio": "None", "PEGRatio": "None", "BookValue": "1.402", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-1.41", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.45", "ReturnOnEquityTTM": "-0.84", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-1.41", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "14.33", "AnalystRatingStrongBuy": "2", "AnalystRatingBuy": "7", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "4.506", "EVToRevenue": "-", "EVToEBITDA": "-2.469", "Beta": "1.138", "52WeekHigh": "7.18", "52WeekLow": "1.285", "50DayMovingAverage": "5.52", "200DayMovingAverage": "3.359", "SharesOutstanding": "149056000", "SharesFloat": "111257000", "PercentInsiders": "0.334", "PercentInstitutions": "82.337", "DividendDate": "None", "ExDividendDate": "None"}